Personalized Medicine Meets the Real World - Pharmaceutical Executive


Personalized Medicine Meets the Real World
A wave of genomic medicines is coming down the pipeline, and they're going

Pharmaceutical Executive

The complexity of multiple requirements often leads researchers to provide two different consent forms—one for the overall research project and the other specifically focused on issues relating to genetics (see "Biology of an Informed Consent Form," page 84). For example, in the general consent form, patients would agree to provide a sample of blood. However, the genomics consent form must identify the specific types of genetic testing to be performed, what happens to the samples should a subject withdraw from the study, and whether or not patients will be notified of results.

There's also a host of ethical issues that come along with any research related to patients and their genetic information. Pharma companies must figure out how they will handle the issues associated with screening for "high-penetrance genes"—highly predictive mutations that signal a major risk of disease development—which can cause psychological harm to individuals that discover they carry a substantial risk of developing a serious or fatal disease. Consider, for example, age-related macular degeneration (AMD), a leading cause of vision loss and blindness with no known cure. Researchers recently identified the presence of two important genes as culprits in AMD development. Researchers found that 74 percent of study subjects with AMD had either one or both of these genes, but no protective variants of either gene. How should sponsors handle telling patients they have both of these traits?

Little safety information Personalized medicines should be safer for patients. Just look at the anti-HIV drug Ziagen (abacavir). About five percent of patients taking the drug experience a serious adverse hypersensitivity reaction. But by testing patients, researchers can determine which ones are more likely to have this reaction, and reduce the risk of that side effect to less than one percent.

In practice, however, personalized medicines come to market without much information about delayed side effects and long-term safety and effectiveness. After all, small patient populations mean smaller trials and less data. Genzyme, for example, received approval for Cerezyme to treat Gaucher disease from a pivotal trial based on data from only 30 patients.

Many personalized therapies are fast-tracked from Phase II to market. They receive accelerated approval because they treat life-threatening or serious debilitating conditions for which there is no satisfactory alternative therapy. That means the total experience with many of these drugs can be based on fewer than 100 subjects. Having so little information about patients' experience means that researchers are less likely to be able to detect safety signals, should any exist.

Good Advice

The cost and complexity of clinical trials are not well suited to understanding how personalized therapies work in the real world, or for providing the value claims payers need to put these drugs on formulary. Observational studies, however, can be an attractive option for companies seeking that information—and a source of continuing connection with a disease community—if designed and executed appropriately.

But small patient populations mean companies must make the most of their interactions with patients and healthcare professionals. Here's some ways companies can make their research proposition attractive, and build lasting relationships with their physicians and patients.

Don't engage in unnecessary experimentation Companies' best chance of attracting participants is to make their research relevant to the marketplace, and attractive to patients and medical professionals. This is particularly important in order to obtain buy-in from sites for post-approval studies. The Office of the Inspector General guidance highlights the possibility that payments and other arrangements for physicians conducting post-approval research might influence their clinician decision-making and cause overuse or inappropriate prescribing. Therefore, in observational research, site reimbursements are generally minimal, at best.

Keep the protocol in line with physicians' offices When companies are bringing a drug to the market, they typically want to define the study population as narrowly as possible to maximize their chance of showing efficacy: otherwise healthy individuals, who are nonsmokers, and aren't taking any other drugs. But in observational studies, the population will vary—patients are going to have co-morbidities, use herbal remedies, live in polluted areas, and may even be taking the drug for an off-label condition. Ensuring that the protocol has broad inclusion criteria and limited exclusion criteria allows companies to capture how the drug works across a broad population, in ways that doctors and patients are actually using the drug.


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here